73873-87-7 Usage
Description
Iloprost is a synthetic analogue of Prostacyclin (PGI2), a naturally occurring prostaglandin with various physiological effects. It is characterized by its ability to elevate cAMP levels through binding to the prostacyclin receptor (IP receptor), which contributes to its vasodilatory, hypotensive, and antiplatelet aggregation properties.
Uses
Used in Pharmaceutical Industry:
Iloprost is used as a therapeutic agent for the treatment of pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, and ischemia. Its application is based on its ability to dilate blood vessels, reduce blood pressure, and inhibit platelet aggregation, thereby improving blood flow and oxygenation in affected patients.
Used in Cardiovascular Applications:
As a vasodilator, Iloprost is used to improve blood flow and reduce the workload on the heart, making it beneficial for patients with cardiovascular diseases. Its hypotensive effect helps in managing high blood pressure and related complications.
Used in Hematological Applications:
Iloprost's antiplatelet aggregation property makes it useful in preventing blood clot formation, which is crucial for patients at risk of thrombotic events or those undergoing surgical procedures where clot formation could be a concern.
Clinical Use
Iloprost is administered as an inhalation solution of a prostacyclin analog for the treatment of NYHA class III and class
IV PAH. The drug also can be administered as an IV infusion. It is stable at room temperature and to light, with a body
half-life of 30 minutes. Iloprost has approximately 10 times greater potency than prostacyclin as a vasodilator of the
pulmonary blood vessels; this greater potency of inhaled iloprost results from coating of the drug on the alveoli of the
lungs.
Side effects
Studies have
reported minor side effects, such as coughing, headaches, and jaw pain.
Drug interactions
Potentially hazardous interactions with other drugs
Anticoagulants: enhanced anticoagulant effect and
increased risk of bleeding with heparin, coumarins
and phenindione, as iloprost inhibits platelet
aggregation.
Increased risk of bleeding with NSAIDs, aspirin,
clopidogrel, eptifibatide and tirofiban.
Metabolism
On intravenous infusion iloprost is rapidly cleared from
the plasma by oxidation. About 80% of the metabolites
are excreted in urine and 20% in the bile.
Check Digit Verification of cas no
The CAS Registry Mumber 73873-87-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,8,7 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 73873-87:
(7*7)+(6*3)+(5*8)+(4*7)+(3*3)+(2*8)+(1*7)=167
167 % 10 = 7
So 73873-87-7 is a valid CAS Registry Number.
InChI:InChI=1/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18?,19-,20+,21+/m0/s1
